<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Kristian Brock</title>
    <link>https://www.kristianbrock.com/</link>
      <atom:link href="https://www.kristianbrock.com/index.xml" rel="self" type="application/rss+xml" />
    <description>Kristian Brock</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Sat, 01 Jun 2030 13:00:00 +0000</lastBuildDate>
    <image>
      <url>https://www.kristianbrock.com/img/icon-192.png</url>
      <title>Kristian Brock</title>
      <link>https://www.kristianbrock.com/</link>
    </image>
    
    <item>
      <title>Example Talk</title>
      <link>https://www.kristianbrock.com/talk/example/</link>
      <pubDate>Sat, 01 Jun 2030 13:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/talk/example/</guid>
      <description>&lt;div class=&#34;alert alert-note&#34;&gt;
  &lt;div&gt;
    Click on the &lt;strong&gt;Slides&lt;/strong&gt; button above to view the built-in slides feature.
  &lt;/div&gt;
&lt;/div&gt;
&lt;p&gt;Slides can be added in a few ways:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Create&lt;/strong&gt; slides using Academic&#39;s &lt;a href=&#34;https://sourcethemes.com/academic/docs/managing-content/#create-slides&#34;&gt;&lt;em&gt;Slides&lt;/em&gt;&lt;/a&gt; feature and link using &lt;code&gt;slides&lt;/code&gt; parameter in the front matter of the talk file&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Upload&lt;/strong&gt; an existing slide deck to &lt;code&gt;static/&lt;/code&gt; and link using &lt;code&gt;url_slides&lt;/code&gt; parameter in the front matter of the talk file&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Embed&lt;/strong&gt; your slides (e.g. Google Slides) or presentation video on this page using &lt;a href=&#34;https://sourcethemes.com/academic/docs/writing-markdown-latex/&#34;&gt;shortcodes&lt;/a&gt;.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;Further talk details can easily be added to this page using &lt;em&gt;Markdown&lt;/em&gt; and $\rm \LaTeX$ math code.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>CRM Simulation Checklist</title>
      <link>https://www.kristianbrock.com/post/crm-simulations-checklist/</link>
      <pubDate>Wed, 15 Jan 2020 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/post/crm-simulations-checklist/</guid>
      <description>&lt;p&gt;During 2019, I was working on simulations using CRM designs in several different trials.
I found I would frequently get the designs mixed up:&lt;/p&gt;
&lt;blockquote&gt;
&lt;p&gt;&amp;ldquo;We are targeting 20% toxicity this trial, right? No, that was the other trial&amp;hellip;we are targeting 33% here&amp;hellip;&amp;rdquo;&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;Similarly, once or twice, I got to the stage where I wanted to run simulations only to discover we had not specified some important design aspect, like when the trial should stop.
To bring all the pertinent information to the fore, I wrote a checklist.
I would take the list and fill it out for each trial to ensure I had all the right information before I started simulating.
In this post, I describe that checklist.&lt;/p&gt;
&lt;p&gt;Download the checklist as &lt;a href=&#34;https://www.kristianbrock.com/doc/CrmSimulationChecklist-1.0.pdf&#34;&gt;PDF&lt;/a&gt;, &lt;a href=&#34;https://www.kristianbrock.com/doc/CrmSimulationChecklist-1.0.docx&#34;&gt;editable Word version&lt;/a&gt;, or &lt;a href=&#34;https://www.kristianbrock.com/doc/CrmSimulationChecklist-Example-1.0.pdf&#34;&gt;completed example&lt;/a&gt;.&lt;/p&gt;
&lt;h1 id=&#34;checklist&#34;&gt;Checklist&lt;/h1&gt;
&lt;h3 id=&#34;1-doses-under-investigation&#34;&gt;1. Doses under investigation?&lt;/h3&gt;
&lt;p&gt;Put simply, which doses are you investigating?
And how many are there?
In this post, we will refer to the number of doses as $n$.
For the plain vanilla CRM, the doses should be fully orderable, meaning it should be possible to unambiguously state that $a &amp;gt; b$ or $a &amp;lt; b$ for each pair of doses $a, b$.
Incidentally, this is also true of the 3+3.
It is easy to inadvertently violate the &lt;em&gt;total orderability&lt;/em&gt; rule when you have combinations (e.g. is 10mg A + 10mb B a greater or lesser dose than 5mg A + 20mg B?) or when you are varying doses and frequencies (e.g. is 20mg of A each day a greater or lesser dose than 100mg of A once per week?).&lt;/p&gt;
&lt;h3 id=&#34;2-target-toxicity-level&#34;&gt;2. Target toxicity level?&lt;/h3&gt;
&lt;p&gt;What probability of dose-limiting toxicity are you targeting?
CRM and 3+3 are toxicity-chasing designs - they will escalate dose until toxicity is seen.
There must be a rationale for why escalation is anticipated to be beneficial to the patient.
So what probability of toxicity are you targeting?
If it is hard to specify an acceptable target, or the target is very low, that might be a sign that CRM and 3+3 are not suitable approaches.&lt;/p&gt;
&lt;h3 id=&#34;3-skeleton&#34;&gt;3. Skeleton?&lt;/h3&gt;
&lt;p&gt;What is your &lt;em&gt;a-priori&lt;/em&gt; expectation of the rate of toxicity at each dose?
This should be a monotonically-increasing vector of probabilities of length $n$.&lt;/p&gt;
&lt;h3 id=&#34;4-starting-dose&#34;&gt;4. Starting dose?&lt;/h3&gt;
&lt;p&gt;Which dose will you start at?
Having a dose or two to de-escalate to might be preferable in case your toxicity expectations are wrong.&lt;/p&gt;
&lt;h3 id=&#34;5-model-type&#34;&gt;5. Model type?&lt;/h3&gt;
&lt;p&gt;There have been various suggestions for the dose-toxicity curve model.
Will you use the empiric approach, or a one parameter logisitic approach, etc?&lt;/p&gt;
&lt;h3 id=&#34;6-model-parameters&#34;&gt;6. Model parameters?&lt;/h3&gt;
&lt;p&gt;Different model types require different parameters and hyperparameters.
E.g. the empiric model shifts the skeleton up and down as DLT outcomes are evaluated in patients, using a single parameter, often called $\beta$.
That parameter needs a prior distribution.
The default prior on $\beta$ in &lt;a href=&#34;https://cran.r-project.org/package=dfcrm&#34;&gt;dfcrm&lt;/a&gt; is $\beta \sim N(0, 1.34)$.
I will let you research why.&lt;/p&gt;
&lt;h3 id=&#34;7-how-to-select-dose&#34;&gt;7. How to select dose?&lt;/h3&gt;
&lt;p&gt;Will you select the dose with estimate DLT probability closest to target?
Or closest without exceeding?
Will you permit skipping doses in escalation?&lt;/p&gt;
&lt;h3 id=&#34;8-when-to-stop&#34;&gt;8. When to stop?&lt;/h3&gt;
&lt;p&gt;Trials end&lt;sup id=&#34;fnref:1&#34;&gt;&lt;a href=&#34;#fn:1&#34; class=&#34;footnote-ref&#34; role=&#34;doc-noteref&#34;&gt;1&lt;/a&gt;&lt;/sup&gt; - when will your trial end?
What is the maximum sample size?
Do you have a stopping rule for excess toxicity?
Do you want to evaluate a minimum number of patients at the candidate dose before you stop?
Also, check that these constraints do not contradict one another!&lt;/p&gt;
&lt;h3 id=&#34;9-length-of-dlt-assessment-window&#34;&gt;9. Length of DLT assessment window?&lt;/h3&gt;
&lt;p&gt;How long is the DLT assessment window?&lt;/p&gt;
&lt;h2 id=&#34;if-using-non-time-to-event-method&#34;&gt;If using non-time-to-event method:&lt;/h2&gt;
&lt;h3 id=&#34;10-how-to-select-cohort-size&#34;&gt;10. How to select cohort size?&lt;/h3&gt;
&lt;p&gt;Commonly designs have used fixed cohort sizes of three.
But perhaps you want to tolerate flexible cohort sizes of 2-5 patients, depending on the times at which they present.
How will you simulate this?&lt;/p&gt;
&lt;h2 id=&#34;if-using-time-to-event-method&#34;&gt;If using time-to-event method:&lt;/h2&gt;
&lt;h3 id=&#34;11-how-to-calculate-weight-of-observation&#34;&gt;11. How to calculate weight of observation?&lt;/h3&gt;
&lt;p&gt;Under the Time-to-Event CRM (TITE-CRM), censored observations of non-DLT are weighted somewhere between 0 and 1.
Logically, the weight should be a non-increasing function of the length of follow-up.
If DLT is experienced, the weight should be 1.
Several weight functions have been proposed.
A simple option is linear, i.e. 50% of the evaluation period without DLT is considered to be 0.5 non-DLT events.&lt;/p&gt;
&lt;h2 id=&#34;for-simulation&#34;&gt;For simulation:&lt;/h2&gt;
&lt;h3 id=&#34;12-what-is-assumed-true-probdlt&#34;&gt;12. What is assumed true Prob(DLT)?&lt;/h3&gt;
&lt;p&gt;The key simulation parameter, what is the true probability of DLT at each dose?
It will be tempting to choose a true dose-DLT curve that looks similar to your skeleton but do not stop there.
Naturally, a thorough simulation study will look at many true dose-DLT curves, with the sought dose appearing at different positions.
If you have a rule for early stopping, you might want to consider a scenario where the true DLT probabilities are all too high.&lt;/p&gt;
&lt;h2 id=&#34;for-simulation-using-time-to-event-method&#34;&gt;For simulation using time-to-event method:&lt;/h2&gt;
&lt;h3 id=&#34;13-what-is-time-between-patient-arrivals&#34;&gt;13. What is time between patient arrivals?&lt;/h3&gt;
&lt;p&gt;When simulating using the TITE-CRM method, you will need to randomly sample patient arrival times.
For instance, for memoryless waiting times, the exponential distribution would do the job.&lt;/p&gt;
&lt;h3 id=&#34;14-what-is-time-between-patient-arrivals&#34;&gt;14. What is time between patient arrivals?&lt;/h3&gt;
&lt;p&gt;Generally in simulation, you sample whether toxicity will happen in a patient given their assigned dose and the associated probability of DLT using a fraw from a Bernoulli random variable.
Once you have established that toxicity occurs in a given patient, you will need to sample the time of the DLT.
How will you do that?
You might assume for constant hazard, for example, and thus use an exponential distribution.
Obviously, if a patient does not experience DLT then their DLT time is infinite.&lt;/p&gt;
&lt;h1 id=&#34;availability-of-software&#34;&gt;Availability of software&lt;/h1&gt;
&lt;p&gt;Having made all these choices (and it is exhausting to even think of all these things), you then have to find or write code to make it happen.
You may find you do not have the time or programming skill to write exactly what you want and opt for an off-the-shelf solution.
Each of &lt;a href=&#34;https://cran.r-project.org/package=dfcrm&#34;&gt;dfcrm&lt;/a&gt;, &lt;a href=&#34;https://cran.r-project.org/package=bcrm&#34;&gt;bcrm&lt;/a&gt;, and &lt;a href=&#34;https://cran.r-project.org/package=crmPack&#34;&gt;crmPack&lt;/a&gt; offer methods for simulating CRM trials, and my very own &lt;a href=&#34;https://www.kristianbrock.com/project/trialr/&#34;&gt;trialr&lt;/a&gt; will have CRM simulation methods soon.
Each differs in what they offer however (that feels like a blog post for another day).
You may discover that no off-the-shelf package does exactly what you want and find yourself tweaking your choices above in light of what is feasible.
It is an iterative process.&lt;/p&gt;
&lt;h3 id=&#34;read-more&#34;&gt;Read more&lt;/h3&gt;
&lt;p&gt;Graham Wheeler and co-authors &lt;sup id=&#34;fnref:2&#34;&gt;&lt;a href=&#34;#fn:2&#34; class=&#34;footnote-ref&#34; role=&#34;doc-noteref&#34;&gt;2&lt;/a&gt;&lt;/sup&gt; wrote a tutorial for designing dose-finding trials using the CRM.
You can read more about that article &lt;a href=&#34;https://www.kristianbrock.com/publication/crm-tutorial/&#34;&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;h3 id=&#34;footnotes&#34;&gt;Footnotes&lt;/h3&gt;
&lt;section class=&#34;footnotes&#34; role=&#34;doc-endnotes&#34;&gt;
&lt;hr&gt;
&lt;ol&gt;
&lt;li id=&#34;fn:1&#34; role=&#34;doc-endnote&#34;&gt;
&lt;p&gt;even &lt;a href=&#34;http://www.stampedetrial.org/&#34;&gt;STAMPEDE&lt;/a&gt;, one imagines. &lt;a href=&#34;#fnref:1&#34; class=&#34;footnote-backref&#34; role=&#34;doc-backlink&#34;&gt;&amp;#x21a9;&amp;#xfe0e;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li id=&#34;fn:2&#34; role=&#34;doc-endnote&#34;&gt;
&lt;p&gt;Wheeler, G.M., Mander, A.P., Bedding, A., Brock, K., Cornelius, V., Grieve, A.P., Jaki, T., Love, S.B., Odondi, L., Weir, C.J., Yap, C., Bond, S.J., 2019. How to design a dose-finding study using the continual reassessment method. BMC Medical Research Methodology 19. &lt;a href=&#34;https://doi.org/10.1186/s12874-018-0638-z&#34;&gt;https://doi.org/10.1186/s12874-018-0638-z&lt;/a&gt; &lt;a href=&#34;#fnref:2&#34; class=&#34;footnote-backref&#34; role=&#34;doc-backlink&#34;&gt;&amp;#x21a9;&amp;#xfe0e;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ol&gt;
&lt;/section&gt;
</description>
    </item>
    
    <item>
      <title>First post</title>
      <link>https://www.kristianbrock.com/post/first-post/first-post/</link>
      <pubDate>Fri, 27 Dec 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/post/first-post/first-post/</guid>
      <description>


&lt;p&gt;I have started this site to record things I am working on in R during my duties as an academic clinical trial statistician.&lt;/p&gt;
&lt;p&gt;Fingers crossed.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>PePS2</title>
      <link>https://www.kristianbrock.com/project/peps2/</link>
      <pubDate>Fri, 27 Dec 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/project/peps2/</guid>
      <description>&lt;h3 id=&#34;summary&#34;&gt;Summary&lt;/h3&gt;
&lt;p&gt;PePS2 is a phase II trial of pembrolizumab in performance status 2 (PS2) non-small-cell lung cancer (NSCLC) patients.
It is run by the &lt;a href=&#34;https://www.birmingham.ac.uk/research/activity/mds/trials/crctu/&#34;&gt;Cancer Research UK Clinical Trials Unit&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;PePS2 is an important trial to me because I developed the analysis model as part of my PhD thesis and worked on the trial from almost the very beginning.
I published a trial design paper and am glad to say that the trial results are currently under peer review.
The investigators and I hope this trial will provide much-needed and much-sought evidence on the merits of giving this PD-L1 blockade drug to PS2 NSCLC patients&lt;/p&gt;
&lt;h3 id=&#34;design&#34;&gt;Design&lt;/h3&gt;
&lt;p&gt;I became involved in PePS2 shortly after joining the trials unit in 2014.
The trial called for a design that evaluated co-primary response and toxicity outcomes.
Naturally, this suggests a Bryant &amp;amp; Day optimal design.
However, published data in performance status 0 &amp;amp; 1 NSCLC patients showed that the PD-L1 tumour proportion score biomarker was strongly predictive of response.
There was also evidence that first-line patients did better than subsequent-line patients.
We expected each of these variables to remain predictive in the performance status 2 population and wanted to stratify the analysis by these variables.
Unfortunately, Bryant &amp;amp; Day&#39;s design assumes an homogeneous population so does not admit explanatory variables.&lt;/p&gt;
&lt;p&gt;I happened to be working on a dose-finding trial at the time that used the EffTox design of Thall &amp;amp; Cook (2004) to appraise joint efficacy and toxicity rates at different doses of experimental agents.
It struck me on a cycle home that the EffTox design could be adjusted with variables reflecting PD-L1 and line-of-therapy status in place of dose to study our co-primary outcomes whilst adjusting for our putative predictive factors.
I worked up the design as part of my PhD, eventually published a design paper, and used the model to conduct a Bayesian analysis of the outcomes in a results manuscript that is currently in peer-review.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>trialr</title>
      <link>https://www.kristianbrock.com/project/trialr/</link>
      <pubDate>Fri, 27 Dec 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/project/trialr/</guid>
      <description>&lt;p&gt;&lt;code&gt;trialr&lt;/code&gt; is an R package that implements Bayesian clinical trial design in &lt;a href=&#34;https://mc-stan.org/&#34;&gt;Stan&lt;/a&gt;, a modern enviroment for probabilistic programming that implements Hamiltonian Monte Carlo Markov Chain sampling.
Bayesian models are relatively abundant in early phase clinical trials where information is scarce and sensible inference is required practically from the moment the trial begins.&lt;/p&gt;
&lt;p&gt;&lt;code&gt;trialr&lt;/code&gt; implements:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;the Contimual Reassessment Method (CMR) for toxicity-based dose-finding;&lt;/li&gt;
&lt;li&gt;the time-to-event CRM for late-onset toxicity in dose-finding;&lt;/li&gt;
&lt;li&gt;the EffTox for toxicity- and efficacy-based dose-finding;&lt;/li&gt;
&lt;li&gt;Wason &amp;amp; Seaman&#39;s Augmented Binary method for fusing continuous and binary outcomes in phase II;&lt;/li&gt;
&lt;li&gt;a hierarchical model of binary responses on related subgroups;&lt;/li&gt;
&lt;li&gt;and more.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;trialr is available on CRAN and is listed on my GitHub page.
There is a manuscript currently under peer-review (pre-print linked below) and it has been used to analyse outcomes in a forthcoming set of clinical trial results.&lt;/p&gt;
&lt;p&gt;CRAN listing&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://cran.r-project.org/web/packages/trialr/index.html&#34;&gt;https://cran.r-project.org/web/packages/trialr/index.html&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;Source code&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://github.com/brockk/trialr&#34;&gt;https://github.com/brockk/trialr&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;Documentation&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://brockk.github.io/trialr/&#34;&gt;https://brockk.github.io/trialr/&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
</description>
    </item>
    
    <item>
      <title>A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates</title>
      <link>https://www.kristianbrock.com/publication/peps2-design/</link>
      <pubDate>Fri, 22 Nov 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/publication/peps2-design/</guid>
      <description>&lt;h3 id=&#34;about-this-publication&#34;&gt;About this publication&lt;/h3&gt;
&lt;p&gt;Getting this paper published was a big deal for me because it was the first design idea I had had that was completely my own.
Well, so I thought.
An erudite peer-reviewer pointed out that the method (which I had named Bayesian Evaluation of Bivariate Outcomes and Predictive variables, or BEBOP) was actually a special case of a design by Thall, Nguyen &amp;amp; Estey.
In response, I re-wrote the paper presenting the design as a novel refinement of their method suitable for phase II trials, called P2TNE for &lt;em&gt;Phase II Thall Nguyen &amp;amp; Estey&lt;/em&gt;.
Anyway, after being rejected twice from big journals, it was a big relief to get the paper published in the BAYSM2018 conference proceedings.
It was especially classy of Springer to give a complementary hard cover copy of the book to each contributing author.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia - The CLARITY Study</title>
      <link>https://www.kristianbrock.com/publication/clarity-results/</link>
      <pubDate>Thu, 11 Jul 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/publication/clarity-results/</guid>
      <description>&lt;h3 id=&#34;about-this-publication&#34;&gt;About this publication&lt;/h3&gt;
&lt;p&gt;This publication is important to me because Clarity was my first successful grant application.
It is a simple trial with modest sample size but the results are absolutely amazing, with an iwCLL response rate of 89% and minimum disease negative status achieved in the peripheral blood of 53% of patients.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>trialr - Bayesian Clinical Trial Designs in R and Stan</title>
      <link>https://www.kristianbrock.com/publication/trialr/</link>
      <pubDate>Sat, 29 Jun 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/publication/trialr/</guid>
      <description>&lt;h3 id=&#34;about-this-publication&#34;&gt;About this publication&lt;/h3&gt;
&lt;p&gt;I became aware of Stan whilst working on some Bayesian clinical trial designs.
I recall using Monte Carlo integration to resolve six-dimensional integrals to estimate posterior means and thinking that there must be a better way.
In fact, there were probably many better ways.
However, I doubt any would be as good as Stan, a probabilistic programming language and Hamiltonion Monte Carlo Markov Chain sampler.
This manuscript is my first sole-author attempt at research.
It was particularly pleasing to implement James Wason and Shaun Seaman&#39;s augmented binary method, an approach that will surely feature strongly if we are to wean ourselves off information-light binary response variables.
&lt;code&gt;trial&lt;/code&gt; is on CRAN.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Slides</title>
      <link>https://www.kristianbrock.com/slides/example/</link>
      <pubDate>Tue, 05 Feb 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/slides/example/</guid>
      <description>&lt;h1 id=&#34;create-slides-in-markdown-with-academic&#34;&gt;Create slides in Markdown with Academic&lt;/h1&gt;
&lt;p&gt;&lt;a href=&#34;https://sourcethemes.com/academic/&#34;&gt;Academic&lt;/a&gt; | &lt;a href=&#34;https://sourcethemes.com/academic/docs/managing-content/#create-slides&#34;&gt;Documentation&lt;/a&gt;&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id=&#34;features&#34;&gt;Features&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;Efficiently write slides in Markdown&lt;/li&gt;
&lt;li&gt;3-in-1: Create, Present, and Publish your slides&lt;/li&gt;
&lt;li&gt;Supports speaker notes&lt;/li&gt;
&lt;li&gt;Mobile friendly slides&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;
&lt;h2 id=&#34;controls&#34;&gt;Controls&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;Next: &lt;code&gt;Right Arrow&lt;/code&gt; or &lt;code&gt;Space&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Previous: &lt;code&gt;Left Arrow&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Start: &lt;code&gt;Home&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Finish: &lt;code&gt;End&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Overview: &lt;code&gt;Esc&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Speaker notes: &lt;code&gt;S&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Fullscreen: &lt;code&gt;F&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;Zoom: &lt;code&gt;Alt + Click&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://github.com/hakimel/reveal.js#pdf-export&#34;&gt;PDF Export&lt;/a&gt;: &lt;code&gt;E&lt;/code&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;
&lt;h2 id=&#34;code-highlighting&#34;&gt;Code Highlighting&lt;/h2&gt;
&lt;p&gt;Inline code: &lt;code&gt;variable&lt;/code&gt;&lt;/p&gt;
&lt;p&gt;Code block:&lt;/p&gt;
&lt;pre&gt;&lt;code class=&#34;language-python&#34;&gt;porridge = &amp;quot;blueberry&amp;quot;
if porridge == &amp;quot;blueberry&amp;quot;:
    print(&amp;quot;Eating...&amp;quot;)
&lt;/code&gt;&lt;/pre&gt;
&lt;hr&gt;
&lt;h2 id=&#34;math&#34;&gt;Math&lt;/h2&gt;
&lt;p&gt;In-line math: $x + y = z$&lt;/p&gt;
&lt;p&gt;Block math:&lt;/p&gt;
&lt;p&gt;$$
f\left( x \right) = ;\frac{{2\left( {x + 4} \right)\left( {x - 4} \right)}}{{\left( {x + 4} \right)\left( {x + 1} \right)}}
$$&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id=&#34;fragments&#34;&gt;Fragments&lt;/h2&gt;
&lt;p&gt;Make content appear incrementally&lt;/p&gt;
&lt;pre&gt;&lt;code&gt;{{% fragment %}} One {{% /fragment %}}
{{% fragment %}} **Two** {{% /fragment %}}
{{% fragment %}} Three {{% /fragment %}}
&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;Press &lt;code&gt;Space&lt;/code&gt; to play!&lt;/p&gt;
&lt;p&gt;&lt;span class=&#34;fragment &#34; &gt;
One
&lt;/span&gt;
&lt;span class=&#34;fragment &#34; &gt;
&lt;strong&gt;Two&lt;/strong&gt;
&lt;/span&gt;
&lt;span class=&#34;fragment &#34; &gt;
Three
&lt;/span&gt;&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;A fragment can accept two optional parameters:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;code&gt;class&lt;/code&gt;: use a custom style (requires definition in custom CSS)&lt;/li&gt;
&lt;li&gt;&lt;code&gt;weight&lt;/code&gt;: sets the order in which a fragment appears&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;
&lt;h2 id=&#34;speaker-notes&#34;&gt;Speaker Notes&lt;/h2&gt;
&lt;p&gt;Add speaker notes to your presentation&lt;/p&gt;
&lt;pre&gt;&lt;code class=&#34;language-markdown&#34;&gt;{{% speaker_note %}}
- Only the speaker can read these notes
- Press `S` key to view
{{% /speaker_note %}}
&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;Press the &lt;code&gt;S&lt;/code&gt; key to view the speaker notes!&lt;/p&gt;
&lt;aside class=&#34;notes&#34;&gt;
  &lt;ul&gt;
&lt;li&gt;Only the speaker can read these notes&lt;/li&gt;
&lt;li&gt;Press &lt;code&gt;S&lt;/code&gt; key to view&lt;/li&gt;
&lt;/ul&gt;
&lt;/aside&gt;
&lt;hr&gt;
&lt;h2 id=&#34;themes&#34;&gt;Themes&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;black: Black background, white text, blue links (default)&lt;/li&gt;
&lt;li&gt;white: White background, black text, blue links&lt;/li&gt;
&lt;li&gt;league: Gray background, white text, blue links&lt;/li&gt;
&lt;li&gt;beige: Beige background, dark text, brown links&lt;/li&gt;
&lt;li&gt;sky: Blue background, thin dark text, blue links&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;
&lt;ul&gt;
&lt;li&gt;night: Black background, thick white text, orange links&lt;/li&gt;
&lt;li&gt;serif: Cappuccino background, gray text, brown links&lt;/li&gt;
&lt;li&gt;simple: White background, black text, blue links&lt;/li&gt;
&lt;li&gt;solarized: Cream-colored background, dark green text, blue links&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;

&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;/img/boards.jpg&#34;
  &gt;

&lt;h2 id=&#34;custom-slide&#34;&gt;Custom Slide&lt;/h2&gt;
&lt;p&gt;Customize the slide style and background&lt;/p&gt;
&lt;pre&gt;&lt;code class=&#34;language-markdown&#34;&gt;{{&amp;lt; slide background-image=&amp;quot;/img/boards.jpg&amp;quot; &amp;gt;}}
{{&amp;lt; slide background-color=&amp;quot;#0000FF&amp;quot; &amp;gt;}}
{{&amp;lt; slide class=&amp;quot;my-style&amp;quot; &amp;gt;}}
&lt;/code&gt;&lt;/pre&gt;
&lt;hr&gt;
&lt;h2 id=&#34;custom-css-example&#34;&gt;Custom CSS Example&lt;/h2&gt;
&lt;p&gt;Let&#39;s make headers navy colored.&lt;/p&gt;
&lt;p&gt;Create &lt;code&gt;assets/css/reveal_custom.css&lt;/code&gt; with:&lt;/p&gt;
&lt;pre&gt;&lt;code class=&#34;language-css&#34;&gt;.reveal section h1,
.reveal section h2,
.reveal section h3 {
  color: navy;
}
&lt;/code&gt;&lt;/pre&gt;
&lt;hr&gt;
&lt;h1 id=&#34;questions&#34;&gt;Questions?&lt;/h1&gt;
&lt;p&gt;&lt;a href=&#34;https://spectrum.chat/academic&#34;&gt;Ask&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://sourcethemes.com/academic/docs/managing-content/#create-slides&#34;&gt;Documentation&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>How to design a dose-finding study using the continual reassessment method</title>
      <link>https://www.kristianbrock.com/publication/crm-tutorial/</link>
      <pubDate>Fri, 18 Jan 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/publication/crm-tutorial/</guid>
      <description>&lt;h3 id=&#34;about-this-publication&#34;&gt;About this publication&lt;/h3&gt;
&lt;p&gt;I had been a trial statistician about 6 months when I attended an NIHR workshop on early phase trial methodology in 2014.
The topic of the day was the trials community&#39;s over-reliance on rule-based dose-finding methods like 3+3.
This tutorial paper was produced by a group of attendees to promote model-based methods.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Combination Lenalidomide and Azacitidine - A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia</title>
      <link>https://www.kristianbrock.com/publication/viola-results/</link>
      <pubDate>Thu, 17 Jan 2019 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/publication/viola-results/</guid>
      <description>&lt;h3 id=&#34;about-this-publication&#34;&gt;About this publication&lt;/h3&gt;
&lt;p&gt;This paper is important to me because Viola was the first dose-finding trial that I worked on.
It uses a CRM model to identify a dose of lenalidomide that is tolerable when given with azacitidine to AML and MDS patients.
This was also one of my first published sets of trial results.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Implementing the EffTox dose-finding design in the Matchpoint trial</title>
      <link>https://www.kristianbrock.com/publication/matchpoint-design/</link>
      <pubDate>Thu, 20 Jul 2017 00:00:00 +0000</pubDate>
      <guid>https://www.kristianbrock.com/publication/matchpoint-design/</guid>
      <description>&lt;h3 id=&#34;about-this-publication&#34;&gt;About this publication&lt;/h3&gt;
&lt;p&gt;This was my first first-author publication and a chapter in my PhD thesis.
Working with EffTox was great, but challenging at times.
The seamless phase I/II approach to dose-finding, where efficacy and toxicity outcomes guide dose selection, has never been more important in this era of targeted therapies in oncology.
However, the EffTox design and the suite of phase I/II methods in general have been relatively underutilised.
We hope this paper demonstrating our experiences with EffTox will inspire early phase trialists to look further than the 3+3.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
